Medical news websites, like MedPage today and Medscape, use doctors to review stories from meetings. Today Adam J. Carinci, and anesthesiologist and pain medicine doc at MGH reviews Conflict on Clopidogrel Response Genetics from the ongoing European Society of Cardiology meeting:
STOCKHOLM — Reduced clopidogrel (Plavix) efficacy associated with certain genomic variants was confirmed in two new analyses but not in a third, researchers found.
In the CURE trial of patients with acute coronary syndromes without ST-segment elevation, clopidogrel significantly reduced the rate of cardiovascular death, MI, or stroke compared with placebo, regardless of CYP2C19 genotype (HR 0.71, 95% CI 0.60 to 0.84), according to Guillaume Paré, MD, of McMaster University in Hamilton, Ontario, and colleagues.
The CURE and ACTIVE A studies were funded by Sanofi-Aventis and Bristol-Myers Squibb, which co-market clopidogrel.
Also from the same Medpage story:
The second Lancet study, by Jessica Mega, MD, of Brigham and Women’s Hospital and Harvard in Boston, and colleagues, reported a similar analysis of the TRITON–TIMI 38 trial, which compared clopidogrel with prasugrel (Effient) in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
The main trial results showed that prasugrel significantly reduced major ischemic events but increased major bleeding.
The TIMI study group received research support from Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, Schering Plough/Merck, Johnson & Johnson, and Bayer Healthcare.
Mega reported receiving grant support from the NIH and consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, and AstraZeneca. Her co-authors reported extensive relationships with industry. Two of the study authors are employed by Eli Lilly and one is employed by Daiichi Sankyo.esc.bmp
